Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

PAD is considered the first and most frequent manifestation of cardiovascular disease in patients with diabetes. There are few therapeutic and interventional options for patients ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

N) has reported new Phase IIIb data showing its GLP-1 drug semaglutide, in both oral and injectable forms, led to significant health benefits in adults with type 2 diabetes facing cardiovascular ...

Medical professionals point out that functional impairment in individuals with PAD is often overlooked in its early stages ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...